drugset / Trial / NCT02465606
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.
Timeline
- Start
- 2015-07-30
- Primary completion
- 2016-05-30
- Completion
- 2016-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrocortisone | Other / unclassified | 2.5 % | Topical |
| Subject | Lebrikizumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Triamcinolone Acetonide | Other / unclassified | 0.1 % | Topical |